Sangamo Therapeutics, Inc (SGMOQ) stock
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Earnings
Sangamo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Sangamo Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | $1.40M | – | -$0.08 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026after the close | $14.20M | +86.8% | -$0.11 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $600.00K | -98.8% | -$0.11 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $18.30M | +6000.0% | -$0.08 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 17, 2025after the close | $7.60M | – | -$0.11 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $49.40M | – | $0.04 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $300.00K | – | -$0.18 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $500.00K | – | -$0.27 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 13, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 5, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 28, 2020before the open | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 6, 2019after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Sangamo Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| non-GAAP total operating expensesnon-GAAP | FY2026 | $100.00M – $120.00M | – | New | May 14, 2026 |
| total operating expensesGAAP | FY2026 | $110.00M – $130.00M | – | New | May 14, 2026 |
| non-GAAP total operating expensesnon-GAAP | FY2026 | $110.00M – $120.00M | – | New | Mar 30, 2026 |
| total operating expensesGAAP | FY2026 | $120.00M – $140.00M | – | New | Mar 30, 2026 |
Guidance history
Every forecast Sangamo Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| May 14, 2026 | non-GAAP total operating expenses | FY2026 | $100.00M – $120.00M | New |
| May 14, 2026 | total operating expenses | FY2026 | $110.00M – $130.00M | New |
| Mar 30, 2026 | non-GAAP total operating expenses | FY2026 | $110.00M – $120.00M | New |
| Mar 30, 2026 | total operating expenses | FY2026 | $120.00M – $140.00M | New |
| Nov 6, 2025 | non-GAAP total operating expenses | FY2025 | $125.00M – $145.00M | Reaffirmed |
| Nov 6, 2025 | total operating expenses | FY2025 | $135.00M – $155.00M | Reaffirmed |
| Aug 7, 2025 | non-GAAP total operating expenses | FY2025 | $125.00M – $145.00M | New |
| Aug 7, 2025 | total operating expenses | FY2025 | $135.00M – $155.00M | New |
| Mar 17, 2025 | non-GAAP total operating expenses | FY2025 | $125.00M – $145.00M | New |
| Mar 17, 2025 | total operating expenses | FY2025 | $135.00M – $155.00M | New |
| Nov 12, 2024 | non-GAAP total operating expenses | FY2024 | $125.00M – $145.00M | Reaffirmed |
| Nov 12, 2024 | total operating expenses | FY2024 | $150.00M – $170.00M | Reaffirmed |
| Aug 6, 2024 | non-GAAP total operating expenses | FY2024 | $125.00M – $145.00M | New |
| Aug 6, 2024 | total operating expenses | FY2024 | $150.00M – $170.00M | New |
| May 9, 2024 | non-GAAP total operating expenses | FY2024 | $125.00M – $145.00M | New |
| May 9, 2024 | total operating expenses | FY2024 | $145.00M – $165.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Sangamo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- News
- Update
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Update
See a number that looks wrong?